BioSpace News Archive

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to extend their rolling submission to the U.S. Food and Drug Administration (FDA) seeking to amend the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine to include children 6 months through 4 years of age, which had been requested by FDA.

AbCellera (Nasdaq: ABCL) today announced that bebtelovimab (LY-CoV1404), the second antibody developed through AbCellera’s collaboration with Eli Lilly and Company (Lilly), has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).

Blueprint Medicines Corporation announced its participation in the following upcoming investor conferences.

Inivata, a leader in liquid biopsy, announced clinical validation data for its RaDaRTM liquid biopsy test in head and neck squamous cell carcinoma.

Photocure ASA, The Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals has obtained the Phase III clinical trial application approval from the National Medical Products Administration of China for Hexvix®.

Humanigen, Inc. announced that Timothy E. Morris, COO/CFO, will be presenting at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually through the 17th.

Axsome Therapeutics, Inc. announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 1:40 PM Eastern Time.

Sio Gene Therapies Inc., a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, provided corporate updates and financial results for its fiscal third quarter ended December 31, 2021.

Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022, at 9:20 a.m. EST.

Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, announced that its New Drug Application for poziotinib has been accepted for review by the U.S. Food and Drug Administration.